Pfizer’s Acquisition of Metsera’s Obesity Drugs
Summary:
Pfizer has acquired Metsera, gaining access to investigational obesity drugs that combine GLP-1 and amylin receptor agonists. The deal is part of Pfizer’s strategy to expand its obesity treatment portfolio by leveraging combination therapies designed to address weight management.
Bristol Myers’ Iberdomide Shows Results in Multiple Myeloma Trial
Summary:
Bristol Myers presented data from the EXCALIBER trial evaluating iberdomide for relapsed or refractory multiple myeloma. The study met its primary endpoint, showing a statistically significant improvement in progression-free survival compared to standard therapies.
Merck’s Subcutaneous Keytruda FDA Approval
Summary:
The FDA approved Merck’s Keytruda for subcutaneous administration, providing a new dosing option beyond intravenous infusion. This formulation aims to improve patient convenience by reducing administration time during cancer immunotherapy.
Acadia Discontinues Carbetocin Development After Prader-Willi Study Failure
Summary:
Acadia Pharmaceuticals discontinued the development of carbetocin for Prader-Willi syndrome after the Phase 3 trial did not meet efficacy endpoints. The company also plans to halt its Levo program under evaluation for other neurological conditions.
RION Collaborates with Lonza to Scale Exosome Therapeutics Manufacturing
Summary:
RION has partnered with Lonza to scale up manufacturing of its exosome-based therapeutics. The collaboration focuses on developing manufacturing capacity to support RION’s clinical and commercial goals for its exosome therapy pipeline.
